4.5 Article

Antiviral effects of micafungin against pteropine orthoreovirus, an emerging zoonotic virus carried by bats

Journal

VIRUS RESEARCH
Volume 339, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.virusres.2023.199248

Keywords

Pteropine orthoreovirus; Antiviral; Fda-approved drug; Micafungin

Categories

Ask authors/readers for more resources

Bat-borne emerging viruses, such as the Ebola virus and Nipah virus, pose a significant threat to public health. In this study, we identified micafungin as a potential antiviral drug against Pteropine orthoreovirus (PRV) and found that it inhibits viral release in human cells through activating the endoplasmic reticulum stress response pathway. This research provides valuable insights into the development of effective treatments for future virus pandemics.
Bat-borne emerging zoonotic viruses cause major outbreaks, such as the Ebola virus, Nipah virus, and/or beta coronavirus. Pteropine orthoreovirus (PRV), whose spillover event occurred from fruits bats to humans, causes respiratory syndrome in humans widely in South East Asia. Repurposing approved drugs against PRV is an effective tool to confront future PRV pandemics. We screened 2,943 compounds in an FDA-approved drug library and identified eight hit compounds that reduce viral cytopathic effects on cultured Vero cells. Real-time quantitative PCR analysis revealed that six of eight hit compounds significantly inhibited PRV replication. Among them, micafungin used clinically as an antifungal drug, displayed a prominent antiviral effect on PRV. Secondly, the antiviral effects of micafungin on PRV infected human cell lines (HEK293T and A549), and their tran-scriptome changes by PRV infection were investigated, compared to four different bat-derived cell lines (FBKT1 (Ryukyu flying fox), DEMKT1 (Leschenault's rousette), BKT1 (Greater horseshoe bat), YUBFKT1 (Eastern bent-wing bats)). In two human cell lines, unlike bat cells that induce an IFN-gamma response pathway, an endoplasmic reticulum stress response pathway was commonly activated. Additionally, micafungin inhibits viral release rather than suppressing PRV genome replication in human cells, although it was disturbed in Vero cells. The target of micafungin's action may vary depending on the animal species, but it must be useful for human purposes as a first choice of medical care.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available